Bruton Tyrosine Kinase (BTK) inhibitor

News

Novel drug to tackle inflammatory diseases begins trial

An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Bruton Tyrosine Kinase (BTK) inhibitor

Editor's Picks